This document describes research aimed at developing selective inhibitors of human aldose reductase (hALR2) that prevent the reduction of glutathione-conjugated aldehydes without inhibiting the reduction of toxic lipid aldehydes. The researchers obtained the hALR2 gene, expressed and purified the protein, and developed an assay using NADPH to test hALR2 activity. Their goals are to use computational modeling to identify inhibitors that selectively target glutathione-tagged substrates in order to inhibit pathways linked to cancer growth and metastasis while allowing reduction of other toxic aldehydes.